N/A
N=8
Telehealth-Clinical Advocacy Project
Substance Use
Bottom Line
View on ClinicalTrials.gov: NCT04911426 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Percent of Participants Who Received One or More Referrals During the 12-week Intervention. — 4 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Telehealth (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Texas Christian University
- Primary completion
- Jul 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent of Participants Who Received One or More Referrals During the 12-week Intervention. |
4 | — |
| PRIMARY Texas Christian University Drug Screen 5 Severity Score From Baseline to Post Intervention at Week 12 |
9.25; 9.75 | — |
Summary
The purpose of this study is to develop a clinical telehealth intervention and test the feasibility of integrating telehealth within a police opioid county diversion program.
Eligibility Criteria
Inclusion Criteria
Individuals interested in joining the study will be
- Enrolled in the A Way Out Opioid Diversion Program (ODP),
- At least 18 years of age,
- Able to speak and understand English,
- Have a history of opioid, alcohol, or other substance use within last 12 months,
- Be willing to provide the research team with access to treatment records,
- Have access to a phone, tablet or computer for the informed consent activity, and
- Have a mailing address to receive a study phone issued to consented participants
Exclusion Criteria
Individuals not eligible for the study are
- Not currently enrolled in the A Way Out Opioid Diversion Program on the day of consent,
- Under the age of 18 on the day of consent,
- Unable to speak and understand English,
- Have a history of past opioid, alcohol, or other substance use longer than 12 months ago with no use of opioids in the last 12 months,
- Unwilling to authorize the research team to access treatment records,
- Without access to a phone, tablet or computer to complete the informed consent activity,
- Without a mailing address
Data sourced from ClinicalTrials.gov (NCT04911426). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.